Arkolith/Insider Trading/THRX/Form 4

Dahms Bradford D.

Chief Financial OfficerTheseus Pharmaceuticals, Inc. (THRX) · full profile →Form 4 · filed Dec 22, 2021
Net Buying
Open-Market Buys
$20K
Open-Market Sells
$0
Net Open-Market Flow
$20K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 21, 2021Buy(P)2K$10.15$20K2K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899243-21-049427) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML